Related references
Note: Only part of the references are listed.Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis
Patricia Barrionuevo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Women's Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review
Patricia Barrionuevo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Novel actions of sclerostin on bone
Gill Holdsworth et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2019)
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2019)
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Bente L. Langdahl et al.
LANCET (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study
J. -H. Kang et al.
OSTEOPOROSIS INTERNATIONAL (2013)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Share Paper
